Pulmonary Fibrosis in COVID-19 Patients
Mathews Journal of Cardiology · 2023
DOI: 10.30654/mjc.10029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mathews Journal of Cardiology, 2023. Verfasst von Eslami Vahid und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Early analysis suggests the prevalence of post COVID 19fibrosis is approximately a fifth to a third of cured patients and 7%-8% are severe.Initiation and advancement of pulmonary fibrosis is caused by inflammation.
Method
In brief, the study population included 107 patients with a history of admission with COVID-19 infection diagnosis to
Zitieren
APA
Vahid, E., Somaye, F., LangroudiTaraneh, F., Eshkaftaki, J. K., Alireza, K., & Latif, G. (2023). Pulmonary Fibrosis in COVID-19 Patients. Mathews Journal of Cardiology. https://doi.org/10.30654/mjc.10029
Vancouver
Vahid E, Somaye F, LangroudiTaraneh F, Eshkaftaki JK, Alireza K, Latif G. Pulmonary Fibrosis in COVID-19 Patients. Mathews Journal of Cardiology. 2023. doi:10.30654/mjc.10029
BibTeX
@article{Vahid2023,
author = {Vahid, Eslami and Somaye, Farokhnejad and LangroudiTaraneh, Faghihi and Eshkaftaki, Javad Karami and Alireza, Kashefizade and Latif, Gachkar},
title = {Pulmonary Fibrosis in COVID-19 Patients},
journal = {Mathews Journal of Cardiology},
year = {2023},
doi = {10.30654/mjc.10029}
}
EUVIMED